A case report of COVID-19 associated pulmonary mucormycosis
##plugins.themes.bootstrap3.article.main##
##plugins.themes.bootstrap3.article.sidebar##
Abstract
Hospitalized patients with SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) are at risk for developing secondary fungal infections due to greater incidence of preexisting comorbidities and exposure to iatrogenic factors such as corticosteroid use. We present the case of a 44-year-old Hispanic female discovered unresponsive in her home that was found to have severe hyperglycemia with comorbid COVID-19 (coronavirus disease 2019) associated pneumonia. The patient was intubated and treated with several broad-spectrum antibiotics, remdesivir, and corticosteroids but had little improvement in her clinical status. Bronchoscopy was performed and revealed multiple necrotic lesions in the lungs. Endobronchial biopsy and bronchoalveolar lavage samples revealed pauciseptated hyphae consistent with zygomycetes. The patient was treated with multiple antifungals including voriconazole, micafungin, and amphotericin B. However, despite maximal medical therapy, the patient perished. This case highlights that clinicians must carry a high degree of suspicion and a low threshold to begin treatment for Mucor in diabetics and other immunosuppressed patients.
##plugins.themes.bootstrap3.article.details##
SARS-CoV-2, COVID-19, mucormycisis, diabetes melitus, thoracic CT, remdesivir
2. Mohamed A, Rogers TR, Talento AF. COVID-19 associated invasive pulmonary aspergillosis: Diagnostic and therapeutic challenges. J Fungi (Basel) 2020; 6(3):115. doi: 10.3390/jof6030115. PMID: 32707965; PMCID: PMC7559350.
3. Koehler P, Cornely OA, Böttiger BW, et al. COVID-19 associated pulmonary aspergillosis. Mycoses 2020; 63(6):528-534. doi:10.1111/myc.13096
4. Mehta S, Pandey A: Rhino-orbital mucormycosis associated with COVID-19. Cureus 2020; 12(9):e10726. doi:10.7759/cureus.10726
5. Placik DA, Wesley TL, Nathan WM: Bronchopleural fistula development in the setting of novel therapies for acute respiratory distress syndrome in SARS-CoV-2 pneumonia. Radiol Case Rep 2020; 15(11):2378-2381. 10.1016/j.radcr.2020.09.026
6. Cornely OA, Alastruey-Izquierdo A, Arenz D, et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet 2019; 19(12):e405-e421 doi: 10.1016/S1473-3099(19)30312-3
7. Jeong W, Keighley C, Wolfe R, et al.: The Epidemiology and Clinical Manifestations of Mucormycosis: A Systematic Review and Meta-Analysis of Case Reports. Clin Microbiol Infect 2019; 25(1):26-34. 10.1016/j.cmi.2018.07.011
8. Symptoms of Mucormycosis. (2020): https://www.cdc.gov/fungal/diseases/mucormycosis/symptoms.html Accessed: December 30, 2020
9. Pulmonary Mucormycosis. (2020): https://radiopaedia.org/articles/pulmonary-mucormycosis?lang=us Accessed: December 30, 2020
10. Hammer MM, Madan R, Hatabu H: Pulmonary mucormycosis: radiologic features at presentation and over time. AJR Am J Roentgenology 2018; 210(4):742-747. 10.2214/AJR.17.18792
11. Mucormycosis (zygomycosis). (2020): https://www.uptodate.com/contents/mucormycosis-zygomycosis/print Accessed: December 30, 2020
12. Lanternier F, Poiree S, Elie C, et al.: Prospective pilot study of high-dose (10 mg/kg/day) liposomal amphotericin B (L-AMB) for the initial treatment of mucormycosis. J Antimicrob Chemother 2015; 70(11):3116-3123. 10.1093/jac/dkv236
13. Ibrahim AS, Gebremariam T, Fu Y, Edwards JE Jr, Spellberg B: Combination echinocandin-polyene treatment of murine mucormycosis. Antimicrob Agents Chemother 2008; 52(4):1556-1558. 10.1128/AAC.01458-07
14. Reed C, Bryant R, Ibrahim AS, et al. Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin Infect Disease 2008; 47(3):364-371. 10.1086/589857
Archive of Clinical Cases is protected by copyright and may be used in accordance with copyright and other applicable laws. Content available at www.clinicalcases.eu and our digital applications is intended for personal noncommercial use.
Authors who submit a manuscript for publication in Archive of Clinical Cases agree to the following terms: a. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. b. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. c. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) only after the final version of the manuscript was accepted and published, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access). d. It is compulsory that before submission authors ensure that their work was not published in any other medical journals or pending acceptance for publication and that "Archives of Clinical Cases" is the only beneficiary at that moment if their work/case will be accepted by us.
Guidelines for linking to www.clinicalcases.eu a. The main purpose of the site linking to the Archive of Clinical Casess site should be educational. b. Links should be made to the Archive of Clinical Casess home page (www.clinicalcases.eu) or to the articles abstract. c. It is forbidden to use the Archive of Clinical Casess cover by outside organizations unless permission has been granted in advance, notifying our Secretary. d. Material owned by the Archive of Clinical Cases (including the name, logo, cover, and text) may not be used in any manner that may induce the idea or suggest that the Archive of Clinical Cases is in some way recommending a specific company, product or service. e. You must not use or allow others to access or use, all or any part of our Site or the contents and/or applications on it for commercial purposes without our permission. To seek permission to do anything prohibited by or not contained in these TERMS, or which requires our prior consent or agreement, you can contact us.